Literature DB >> 10988317

RBC antibody persistence.

H Schonewille1, H L Haak, A M van Zijl.   

Abstract

BACKGROUND: A person exposed to foreign blood group antigens may produce antibodies. The persistence of antibodies varies among people and among antibodies. A study was performed to investigate the persistence of clinically significant RBC alloantibodies over a period of 20 years. STUDY DESIGN AND METHODS: A retrospective examination was performed of all records of RBC antibodies in the transfusion laboratory computer database from 1978 through 1997. Records of patients who underwent at least one antibody investigation after an antibody had been detected were studied. The study included all antibodies against the Rh, K, Fy, Jk, and MNs blood group systems. An antibody was regarded as not persistent if, after previous detection, the screening or panel studies became negative for the antibody under study. Anti-D due to RhIg administration was excluded.
RESULTS: An analysis was performed of 480 records consisting of 593 antibodies that fulfilled the criteria. Median antibody follow-up was 10 months (range, 1-240). In 137 patients, 153 (26%) antibodies became undetectable over the course of time. After initial negative screening investigations, 310 antibodies were formed. The antibodies that were still detectable had a median follow-up of 7 months (range, 1-193). A patient's age, sex, and antibody specificity were of no influence on the length of time that antibodies were detectable. Antibodies detected with a more sensitive screening technique were less persistent (p = 0.0002). For 28 patients, detection of antibodies was highly irregular.
CONCLUSIONS: About 25 percent of all antibodies became undetectable over the course of time. The antibody screening technique used, rather than the antibody specificity, affected these results. To prevent delayed hemolytic transfusion reactions, precise antibody documentation is of great importance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10988317     DOI: 10.1046/j.1537-2995.2000.40091127.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  16 in total

1.  A rewarding fresh look at routine blood group data.

Authors:  Willy A Flegel
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

Review 2.  Would a National Antibody Register contribute to improving patient outcomes?

Authors:  Zachary Powell; Nan Jiang; Rajeshwori Shrestha; Denise E Jackson
Journal:  Blood Transfus       Date:  2021-03-12       Impact factor: 3.443

Review 3.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

4.  Clinical strategies for supporting the untransfusable hemorrhaging patient.

Authors:  Gavin M Melmed; Meredith E Hulsey; Mike Newhouse; Houston E Holmes; Edward J Mays
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-10

5.  The persistence of red cell alloantibodies.

Authors:  Roberto Reverberi
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

6.  Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study.

Authors:  Joan Cid; Miguel Lozano; Alyssa Ziman; Kamille A West; Kerry L O'Brien; Michael F Murphy; Silvano Wendel; Alejandro Vázquez; Xavier Ortín; Tor A Hervig; Meghan Delaney; Willy A Flegel; Mark H Yazer
Journal:  Br J Haematol       Date:  2014-10-04       Impact factor: 6.998

7.  Red Blood Cell Alloimmunization in Sickle Cell Disease Patients in Tanzania.

Authors:  E Meda; P M Magesa; T Marlow; C Reid; D J Roberts; J Makani
Journal:  East Afr J Public Health       Date:  2014

Review 8.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

9.  Long-Term follow up after intra-Uterine transfusionS; the LOTUS study.

Authors:  Esther P Verduin; Irene T M Lindenburg; Vivianne E H J Smits-Wintjens; Jeanine M M van Klink; Henk Schonewille; Inge L van Kamp; Dick Oepkes; Frans J Walther; Humphrey H H Kanhai; Ilias I N Doxiadis; Enrico Lopriore; Anneke Brand
Journal:  BMC Pregnancy Childbirth       Date:  2010-12-01       Impact factor: 3.007

10.  Alloimmunization screening after transfusion of red blood cells in a prospective study.

Authors:  Vitor Mendonça Alves; Paulo Roberto Juliano Martins; Sheila Soares; Gislene Araújo; Luciana Cayres Schmidt; Sidneia Sanches de Menezes Costa; Dante Mário Langhi; Helio Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.